CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence for regulatory science and innovation in pharmacogenomics (CERSI-PGx).
Sign Up to like & getrecommendations! Published in 2025 at "British journal of clinical pharmacology"
DOI: 10.1002/bcp.70370
Abstract: Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the… read more here.
Keywords: cyp2c19; genotype testing; cyp2c19 genotype; testing clopidogrel ... See more keywords